PDCD1 and hepatocellular carcinoma: Specifically, atezo/bev therapy, which combines an anti-programmed cell death 1 (PD-1) ligand 1 (PD-L1) antibody with a VEGF antibody, was the first immunotherapy to show efficacy against unresectable HCC [16].